S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.50
+1.82
+10.91%
HHS · Harte Hanks, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$4.00
-0.20
(-4.76%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.00
$4.00
$4.12
52-WEEK RANGE
$4.00
$2.00
$4.67
What's happening
- HHS is down 4.76% today, trading at $4.00. — Live quote
- Volume today (955) is well below its 3-month average of 117,050. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 1
Buy 3
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2025-01-01 (5 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
HHS
+38.87%
vs S&P 500
+27.68%
1-YEAR RETURN
HHS
-36.18%
vs S&P 500
-43.63%
6-MONTH RETURN
HHS
+67.20%
3-MONTH RETURN
HHS
+71.31%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2025-07-26 (Q2 2025)
$-0.05
Est. $—
2024-10-26 (Q3 2024)
$0.02
Est. $0.10
MISS -80.2%
2024-07-26 (Q2 2024)
$1.41
Est. $0.05
BEAT +2692.1%
2024-04-26 (Q1 2024)
$-0.02
Est. $-0.04
BEAT +50.5%
Valuation Measures & Ratios
Enterprise Value4$29.5M
Forward P/E5—
PEG Ratio6-0.06
Price / Sales (TTM1)0.20
Price / Book71.04
EV4 / Revenue0.19
EV4 / EBITDA7.12
Profit Margin-3.70%
Operating Margin-3.15%
Return on Equity (ROE8)-30.13%
Return on Assets (ROA9)-6.30%
Avg Volume (3M)117,050
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $16.7M | $23.8M | $26.9M | $28.7M | $37.6M |
| P/E | -2.02 | -6.53 | -9.38 | -1.01 | -1.33 |
| Price/Sales | 0.11 | 0.15 | 0.16 | 0.17 | 0.21 |
| Price/Book | 1.08 | 1.18 | 1.35 | 1.29 | 1.76 |
| EV/Revenue | 0.09 | 0.12 | 0.12 | 0.14 | 0.16 |
| EV/EBITDA | 17.28 | 3.68 | 2.60 | — | — |
| ROE | -53.76% | -18.11% | -14.44% | -127.78% | -131.90% |
| ROA | -9.37% | -4.03% | -3.10% | -29.91% | -28.09% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short37,517
Change from Prior Settlement+14.33%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -1.7% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -3.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -36.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on HHS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.0M | $37.3M | $39.5M | $38.6M | $41.6M | $47.6M | $45.0M | $45.4M |
| Operating income | -$4.5M | -$768.0K | $509.0K | $34.0K | -$40.0K | $1.9M | $1.4M | $375.0K |
| Net income | -$5.0M | -$628.0K | -$2.3M | -$335.0K | -$392.0K | $142.0K | -$27.8M | -$171.0K |
| EPS (diluted) | $-0.67 | $-0.08 | $-0.31 | $-0.05 | $-0.05 | $0.02 | $-3.84 | $-0.02 |
| EPS (basic) | $-0.67 | $-0.08 | $-0.31 | $-0.05 | $-0.05 | $0.02 | $-3.84 | $-0.02 |
| Operating margin | -$12 | -$2 | $1 | $0 | -$0 | $4 | $3 | $1 |
| Net margin | -$13 | -$2 | -$6 | -$1 | -$1 | $0 | -$62 | -$0 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $88.1M | $90.4M | $91.8M | $92.7M | $95.0M | $100.6M | $101.8M | $108.1M |
| Total liabilities | $72.7M | $70.3M | $71.3M | $72.8M | $72.8M | $79.2M | $80.1M | $87.1M |
| Stockholders' equity | $15.3M | $20.1M | $20.5M | $19.9M | $22.2M | $21.4M | $21.7M | $21.0M |
| Total current assets | $45.4M | $45.8M | $46.3M | $48.7M | $50.0M | $53.7M | $53.6M | $53.8M |
| Total current liabilities | $34.9M | $30.7M | $30.2M | $33.0M | $31.2M | $36.1M | $35.1M | $36.9M |
| Cash & equivalents | $5.2M | $4.5M | $5.6M | $6.5M | $4.7M | $8.7M | $9.8M | $5.9M |
| Accounts receivable | $27.4M | $26.1M | $27.8M | $30.2M | $34.4M | $29.6M | $31.6M | $33.3M |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | $1.8M | $2.1M | $2.0M | $1.7M | $951.0K | $1.3M | $1.4M | $1.5M |
| Property, plant & equipment | $6.9M | $7.8M | $8.4M | $7.9M | $8.0M | $8.5M | $9.0M | $9.3M |
| Goodwill | $295.0K | $295.0K | $295.0K | $295.0K | $295.0K | $295.0K | $295.0K | $1.9M |
| Intangible assets | $273.0K | $322.0K | $370.0K | $418.0K | $466.0K | $514.0K | $563.0K | $2.3M |
| Other non-current assets | $690.0K | $694.0K | $564.0K | $565.0K | $513.0K | $656.0K | $717.0K | $734.0K |
| Accounts payable | $13.2M | $11.1M | $13.1M | $18.1M | $18.6M | $22.0M | $13.4M | $20.9M |
| Accrued liabilities | $6.6M | $6.1M | $5.9M | — | — | — | $8.4M | — |
| Deferred revenue (current) | $2.6M | $2.6M | $813.0K | $2.5M | $1.8M | $2.5M | $1.6M | $3.4M |
| Short-term debt | $3.0M | — | $0 | — | — | — | — | — |
| Other current liabilities | $1.7M | $2.8M | $3.2M | $4.3M | $1.9M | $2.5M | $3.1M | $3.0M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $888.0K | $1.0M | $1.2M | $1.2M | $1.3M | $1.3M | $1.5M | $1.8M |
| Common stock & paid-in capital | $12.2M | $12.2M | $12.2M | $12.2M | $12.2M | $12.2M | $12.2M | $12.2M |
| Retained earnings | $808.2M | $813.2M | $813.8M | $811.6M | $813.9M | $814.2M | $814.6M | $817.1M |
| Accumulated other comprehensive income (loss) | -$14.9M | -$15.0M | -$15.0M | -$13.5M | -$13.3M | -$13.4M | -$13.6M | -$16.4M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.1M | -$575.0K | $737.0K | $3.2M | -$4.8M | -$818.0K | $4.0M | -$2.9M |
| Investing cash flow | $41.0K | -$347.0K | -$1.4M | -$1.0M | -$225.0K | -$103.0K | -$626.0K | -$1.9M |
| Financing cash flow | $2.9M | -$50.0K | -$41.0K | -$155.0K | $778.0K | -$68.0K | -$94.0K | -$163.0K |
| Free cash flow | -$2.0M | -$922.0K | -$686.0K | $2.2M | -$5.1M | -$923.0K | $3.4M | -$4.9M |
| Capital expenditures | -$41.0K | $347.0K | $1.4M | $1.0M | $223.0K | $105.0K | $627.0K | $1.9M |
| Depreciation & amortization | $1.1M | $1.1M | $1.1M | $2.3M | $1.1M | $1.1M | $1.3M | $1.0M |
| Share-based compensation | $221.0K | $218.0K | -$63.0K | $150.0K | $220.0K | -$49.0K | $277.0K | $368.0K |
| Deferred income taxes | -$33.0K | -$25.0K | -$852.0K | -$25.0K | -$15.0K | -$36.0K | $975.0K | -$35.0K |
| Change in accounts receivable | $1.1M | -$589.0K | -$2.6M | -$3.1M | $272.0K | $497.0K | -$2.7M | $3.9M |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | $2.5M | -$1.8M | $910.0K | -$497.0K | -$3.4M | -$175.0K | $1.2M | $980.0K |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | $0 | $0 |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $159.6M | $185.2M | $191.5M | $206.3M | $194.6M |
| Operating income | $386.0K | $2.1M | $3.4M | $15.1M | $7.6M |
| Net income | -$811.0K | -$30.3M | -$1.6M | $36.8M | $15.0M |
| EPS (diluted) | $-0.11 | $-4.15 | $-0.21 | $4.75 | $1.76 |
| EPS (basic) | $-0.11 | $-4.15 | $-0.21 | $4.98 | $1.85 |
| Operating margin | $0 | $1 | $2 | $7 | $4 |
| Net margin | -$1 | -$16 | -$1 | $18 | $8 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Jan '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $91.8M | $101.8M | — | $122.8M | $120.0M |
| Total liabilities | $71.3M | $80.1M | — | $102.9M | $101.2M |
| Stockholders' equity | $20.5M | $21.7M | — | $19.9M | $18.8M |
| Total current assets | $46.3M | $53.6M | — | $65.2M | $66.3M |
| Total current liabilities | $30.2M | $35.1M | — | $48.1M | $43.6M |
| Cash & equivalents | $5.6M | $9.8M | — | $18.4M | $10.4M |
| Accounts receivable | $27.8M | $31.6M | — | $34.3M | $39.7M |
| Inventory | — | — | — | — | — |
| Other current assets | $2.0M | $1.4M | — | $928.0K | $1.6M |
| Property, plant & equipment | $8.4M | $9.0M | — | $8.9M | $10.5M |
| Goodwill | $295.0K | $295.0K | — | $1.9M | $2.4M |
| Intangible assets | $370.0K | $563.0K | — | $2.8M | $3.5M |
| Other non-current assets | $564.0K | $717.0K | — | $1.3M | $1.7M |
| Accounts payable | $13.1M | $13.4M | — | $23.2M | $22.5M |
| Accrued liabilities | $5.9M | $8.4M | — | — | — |
| Deferred revenue (current) | $813.0K | $1.6M | $3.2M | $3.2M | $4.6M |
| Other current liabilities | $3.2M | $3.1M | — | $9.5M | $2.9M |
| Long-term debt | — | — | — | — | $0 |
| Other non-current liabilities | $1.2M | $1.5M | — | $1.9M | $3.3M |
| Common stock & paid-in capital | $12.2M | $12.2M | — | $12.2M | $12.2M |
| Retained earnings | $813.8M | $814.6M | — | $844.9M | $846.5M |
| Accumulated other comprehensive income (loss) | -$15.0M | -$13.6M | — | -$44.1M | -$48.3M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.7M | -$3.0M | $10.5M | $28.8M | -$1.8M |
| Investing cash flow | -$2.8M | -$3.7M | -$2.3M | -$11.5M | -$2.9M |
| Financing cash flow | $514.0K | -$419.0K | -$3.2M | -$15.8M | -$13.4M |
| Free cash flow | -$4.5M | -$6.7M | $7.7M | $23.0M | -$4.8M |
| Capital expenditures | $2.8M | $3.7M | $2.8M | $5.8M | $3.0M |
| Depreciation & amortization | $4.5M | $4.4M | $4.2M | $2.7M | $2.6M |
| Share-based compensation | $258.0K | $1.9M | $1.4M | $2.4M | $1.5M |
| Deferred income taxes | -$928.0K | -$9.3M | -$1.5M | -$19.8M | $0 |
| Change in accounts receivable | -$5.0M | -$2.4M | -$5.7M | -$3.8M | $9.2M |
| Change in inventory | — | — | — | — | — |
| Change in accounts payable | -$3.2M | -$795.0K | $844.0K | $6.2M | -$395.0K |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | $0 | $2.4M | $0 | — |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding HHS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-07-12 to 2026-06-02
Recent transactions
- Most recent: Fisher David Scott (President) — Other acquisition/disposition of 18,790 shares on 2026-06-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Fisher David Scott | President | Other acquisition/disposition | 2026-06-02 | 18,790 |
| Combes Genevieve Claire | Director | Grant / award | 2025-12-09 | 27,861 |
| Radoff Bradley Louis | Director | Grant / award | 2025-12-09 | 27,861 |
| GARRISON DAVID A | Chief Financial Officer | Grant / award | 2025-06-02 | 25,000 |
| Wyman Robert T. | General Counsel | Grant / award | 2025-06-02 | 25,000 |
| Ross Elizabeth | Director | Other acquisition/disposition | 2025-05-23 | 12,048 |
| GRIFFIN JOHN H JR | Director | Other acquisition/disposition | 2025-05-23 | 12,048 |
| Davis Kirk A | Chief Executive Officer | Open market purchase | 2024-08-12 | 7,082 |
| Rosenbach Gary Stephen | 10% owner | Open market purchase | 2023-07-12 | 8,400 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-02 | Fisher David Scott | President | Other acquisition/disposition | 18,790 | $2.62 |
| 2026-06-02 | Fisher David Scott | President | Tax withholding | 7,876 | $2.62 |
| 2026-06-02 | Fisher David Scott | President | Other acquisition/disposition | 18,790 | $2.62 |
| 2025-12-09 | Combes Genevieve Claire | Director | Grant / award | 27,861 | $3.23 |
| 2025-12-09 | Radoff Bradley Louis | Director | Grant / award | 27,861 | $3.23 |
| 2025-06-02 | GARRISON DAVID A | Chief Financial Officer | Grant / award | 25,000 | $4.55 |
| 2025-06-02 | Wyman Robert T. | General Counsel | Grant / award | 25,000 | $4.55 |
| 2025-05-26 | Wyman Robert T. | General Counsel | Other acquisition/disposition | 2,000 | $4.75 |
| 2025-05-26 | Wyman Robert T. | General Counsel | Other acquisition/disposition | 2,000 | $4.75 |
| 2025-05-26 | Wyman Robert T. | General Counsel | Tax withholding | 853 | $4.75 |
| 2025-05-23 | Radoff Bradley Louis | Director | Other acquisition/disposition | 12,048 | $4.56 |
| 2025-05-23 | Radoff Bradley Louis | Director | Other acquisition/disposition | 12,048 | $4.56 |
| 2025-05-23 | Ross Elizabeth | Director | Other acquisition/disposition | 12,048 | $4.56 |
| 2025-05-23 | Ross Elizabeth | Director | Other acquisition/disposition | 12,048 | $4.56 |
| 2025-05-23 | GRIFFIN JOHN H JR | Director | Other acquisition/disposition | 12,048 | $4.56 |
| 2025-05-23 | GRIFFIN JOHN H JR | Director | Other acquisition/disposition | 12,048 | $4.56 |
| 2025-03-04 | Wyman Robert T. | General Counsel | Other acquisition/disposition | 4,166 | $5.01 |
| 2025-03-04 | Wyman Robert T. | General Counsel | Other acquisition/disposition | 4,166 | $5.01 |
| 2025-03-04 | Wyman Robert T. | General Counsel | Tax withholding | 1,777 | $5.01 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 200 | $5.75 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 2 | $5.76 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 245 | $5.77 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 2,853 | $5.78 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 3,306 | $5.80 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 200 | $5.81 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 1,594 | $5.82 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 368 | $5.83 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 200 | $5.84 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 627 | $5.84 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 100 | $5.85 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 3,997 | $5.85 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 1,603 | $5.86 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 84 | $5.87 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 219 | $5.88 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 99 | $5.88 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 117 | $5.89 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 327 | $5.89 |
| 2024-12-05 | Radoff Bradley Louis | Director | Open market purchase | 1,084 | $5.90 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 176 | $5.50 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 1,500 | $5.54 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 282 | $5.55 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 381 | $5.57 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 66 | $5.58 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 703 | $5.59 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 711 | $5.60 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 691 | $5.60 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 270 | $5.61 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 100 | $5.62 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 330 | $5.63 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 100 | $5.64 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 10,124 | $5.64 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 200 | $5.65 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 5,853 | $5.65 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 100 | $5.66 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 16,800 | $5.66 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 100 | $5.67 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 100 | $5.68 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 774 | $5.68 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 590 | $5.69 |
| 2024-12-04 | Radoff Bradley Louis | Director | Open market purchase | 2,824 | $5.70 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-15 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-08-19 | 8-K | 2026-08-19 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-02 | View on SEC.gov → |
| 2026-05-21 | 8-K | 2026-05-21 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-03-18 | 8-K | 2026-03-17 | View on SEC.gov → |
| 2026-03-17 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2025-12-15 | 4 | 2025-12-09 | View on SEC.gov → |
| 2025-12-11 | 4 | 2025-12-09 | View on SEC.gov → |
| 2025-12-10 | 8-K | 2025-12-10 | View on SEC.gov → |
Recent news
Headlines about HHS (Harte Hanks, Inc.). Links open the publisher — we don’t host full articles.
-
Press Release: Chris Pappas Joins Members of Congress in Calling for HHS to Withdraw Head Start Rule Proposal
Quiver Quantitative · 2026-10-22 -
Feds plan to have HHS lawyers represents migrant kids, sparking a backlash
The Detroit News · 2026-10-22 -
HHS launches national kidney care plan
Fierce Healthcare · 2026-10-21 -
HHS Kidney Care Plan Raises Concerns for DaVita (DVA) Amid Positive Analyst Outlook
GuruFocus · 2026-10-21 -
U.S. Senator Ron Wyden Calls on HHS Secretary Robert F. Kennedy, Jr. to Reverse Plans for Trump Administration Lawyers to Represent Unaccompanied Children in Immigration Court
Sierra Sun Times · 2026-10-21 -
HHS Launches Kidney Care Plan Addressing Dialysis Entry Barriers
TOKENPOST · 2026-10-21 -
DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice
PR Newswire · 2026-10-20 -
HHS Launches Kidney Care National Plan, Impacting DaVita Inc (DV
GuruFocus · 2026-10-20
No headlines in this category right now — try “All”.